Stock DNA
Pharmaceuticals & Biotechnology
CNY 37,608 Million (Large Cap)
NA (Loss Making)
NA
0.00%
-0.00
-74.30%
13.44
Revenue and Profits:
Net Sales:
101 Million
(Quarterly Results - Jun 2025)
Net Profit:
-587 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
70.83%
0%
70.83%
6 Months
68.38%
0%
68.38%
1 Year
75.86%
0%
75.86%
2 Years
362.22%
0%
362.22%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Sichuan Biokin Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
37.00%
EBIT Growth (5y)
149.71%
EBIT to Interest (avg)
68.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.56
Tax Ratio
11.95%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2,080.57%
ROE (avg)
42.59%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
13.44
EV to EBIT
-16.88
EV to EBITDA
-17.61
EV to Capital Employed
13.47
EV to Sales
86.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-79.78%
ROE (Latest)
-74.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
101.10
87.70
15.28%
Operating Profit (PBDIT) excl Other Income
-601.10
-336.30
-78.74%
Interest
18.50
9.50
94.74%
Exceptional Items
4.90
13.60
-63.97%
Consolidate Net Profit
-586.50
-338.80
-73.11%
Operating Profit Margin (Excl OI)
-6,189.50%
-4,058.90%
-213.06%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 15.28% vs -52.39% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -73.11% vs -109.78% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,811.20
551.40
953.90%
Operating Profit (PBDIT) excl Other Income
3,760.40
-731.50
614.07%
Interest
43.90
25.40
72.83%
Exceptional Items
11.40
0.00
Consolidate Net Profit
3,707.50
-780.50
575.02%
Operating Profit Margin (Excl OI)
632.80%
-1,448.30%
208.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 953.90% vs -20.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 575.02% vs -176.38% in Dec 2023
About Sichuan Biokin Pharmaceutical Co., Ltd. 
Sichuan Biokin Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






